An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting
dc.authorid | Uslu, Ruchan/0000-0002-9584-6134 | |
dc.authorid | Cicin, Irfan/0000-0002-7584-3868 | |
dc.authorid | MUSTAFA, ÖZGÜROĞLU/0000-0002-8417-8628 | |
dc.authorwosid | Uslu, Ruchan/CAA-9946-2022 | |
dc.authorwosid | Cicin, Irfan/AAQ-5575-2020 | |
dc.authorwosid | MUSTAFA, ÖZGÜROĞLU/A-8234-2016 | |
dc.contributor.author | Cicin, I. | |
dc.contributor.author | Oukkal, M. | |
dc.contributor.author | Mahfouf, H. | |
dc.contributor.author | Mezlini, A. | |
dc.contributor.author | Larbaoui, B. | |
dc.contributor.author | Slim, B. A. | |
dc.contributor.author | Uslu, R. | |
dc.date.accessioned | 2024-06-12T11:20:40Z | |
dc.date.available | 2024-06-12T11:20:40Z | |
dc.date.issued | 2018 | |
dc.department | Trakya Üniversitesi | en_US |
dc.description | 11th European Breast Cancer Conference (EBCC) -- MAR 21-23, 2018 -- Barcelona, SPAIN | en_US |
dc.description.abstract | [Abstract Not Available] | en_US |
dc.identifier.doi | 10.1016/S0959-8049(18)30535-5 | |
dc.identifier.endpage | S103 | en_US |
dc.identifier.issn | 0959-8049 | |
dc.identifier.issn | 1879-0852 | |
dc.identifier.startpage | S102 | en_US |
dc.identifier.uri | https://doi.org/10.1016/S0959-8049(18)30535-5 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14551/25714 | |
dc.identifier.volume | 92 | en_US |
dc.identifier.wos | WOS:000429103100277 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Sci Ltd | en_US |
dc.relation.ispartof | European Journal Of Cancer | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | [No Keywords] | en_US |
dc.title | An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting | en_US |
dc.type | Conference Object | en_US |